Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KLOAQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
scFv(trastuzumab)-PE38KDEL
|
|||||
| Synonyms |
scFv(trastuzumab) PE38KDEL
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Antibody Name |
Trastuzumab scFv
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Pseudomonas exotoxin PE38
|
Payload Info | ||||
| Therapeutic Target |
Eukaryotic elongation factor 2 (EEF2)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 13
|
%
|
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
3
|
pM
|
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 13.00% (Day 3) | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
N87 tumors were implanted to NOD/SCID mice to the size of about 100 mm3 (day 0) and were then treated with ADCs at day 0, day 3 and day 7 at the dosage of 0.166 mg/kg.
|
||||
| In Vivo Model | NCI-N87 CDX model | ||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.00 pM | Positive HER2 expression (HER2 +++/++) | ||
| Method Description |
N87 cells (10000) were seeded in 96-well plates for the IC50 measurements of cell viability. After incubation at 37°C for 16 h, the medium was replaced by fresh normal medium with serum and the cytotoxicity was assessed using the WST-1 reagent after 72 h of incubation at 37°C.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.